132 related articles for article (PubMed ID: 32162270)
1. Pharmacokinetics of Polyethylene Glycol-Modified Canine Uricase Following Single and Multiple Intravenous Injections in Cynomolgus Monkeys.
Li H; Huo J; Sun D; Jiang L; Hu C; Bai Y; Ma X; Zhang H; Shi X; Zhao Z; Zhou J; Lu Y; Zhang C
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):445-451. PubMed ID: 32162270
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
3. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D
Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989
[TBL] [Abstract][Full Text] [Related]
4. Species and sex differences in the blood clearance and immunogenicity of PEGylated uricase: A comparative 26-week toxicity study in rats and monkeys.
Zhang C; Fan K; Luo H; Cheng Y; Lu Y; Zheng J; Chen Z; Xue J; Zhao Q; Zhang M; Ge Y; Hu C; Bai Y; Yang L; Ma X; Chen M; Zhao Z; Shi X
Life Sci; 2020 Aug; 255():116892. PubMed ID: 31610209
[TBL] [Abstract][Full Text] [Related]
5. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
Biggers K; Scheinfeld N
Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
[TBL] [Abstract][Full Text] [Related]
6. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
Hershfield MS; Ganson NJ; Kelly SJ; Scarlett EL; Jaggers DA; Sundy JS
Arthritis Res Ther; 2014 Mar; 16(2):R63. PubMed ID: 24602182
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
[TBL] [Abstract][Full Text] [Related]
8. Determination of PEGylation homogeneity of polyethylene glycol-modified canine uricase.
Li H; Huo J; Sun D; Guo Y; Jiang L; Zhang H; Shi X; Zhao Z; Zhou J; Hu C; Zhang C
Electrophoresis; 2021 Mar; 42(6):693-699. PubMed ID: 33247595
[TBL] [Abstract][Full Text] [Related]
9. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
[TBL] [Abstract][Full Text] [Related]
10. Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol.
Eliason JF; Greway A; Tare N; Inoue T; Bowen S; Dar M; Yamasaki M; Okabe M; Horii I
Stem Cells; 2000; 18(1):40-5. PubMed ID: 10661570
[TBL] [Abstract][Full Text] [Related]
11. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
[TBL] [Abstract][Full Text] [Related]
12. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
Chua CC; Greenberg ML; Viau AT; Nucci M; Brenckman WD; Hershfield MS
Ann Intern Med; 1988 Jul; 109(2):114-7. PubMed ID: 3289428
[TBL] [Abstract][Full Text] [Related]
13. Pegloticase: a novel agent for treatment-refractory gout.
Shannon JA; Cole SW
Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.
Bleyer AJ; Wright D; Alcorn H
Clin Nephrol; 2015 May; 83(5):286-92. PubMed ID: 25816806
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic analysis of intravenous recombinant urate oxidase using an indirect pharmacological response model in healthy subjects.
Cai NF; Cheng ZN; Zi Y; Luo X; Guo X; Liu Z; Zheng LY
Acta Pharmacol Sin; 2014 Nov; 35(11):1447-52. PubMed ID: 25283504
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans.
Sharda N; Khandelwal P; Zhang L; Caceres-Cortes J; Marathe P; Chimalakonda A
Eur J Pharm Sci; 2021 Oct; 165():105928. PubMed ID: 34265405
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of PEG-hemoglobin SB1, a hemoglobin-based oxygen carrier, after its intravenous administration in beagle dogs.
Kwon OS; Chung UT; Chung YB
Arch Pharm Res; 2004 Feb; 27(2):259-64. PubMed ID: 15022731
[TBL] [Abstract][Full Text] [Related]
18. Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart.
Ozer I; Kelly G; Gu R; Li X; Zakharov N; Sirohi P; Nair SK; Collier JH; Hershfield MS; Hucknall AM; Chilkoti A
Adv Sci (Weinh); 2022 Apr; 9(11):e2103672. PubMed ID: 35133079
[TBL] [Abstract][Full Text] [Related]
19. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses.
Ferron GM; Rochdi M; Jusko WJ; Scherrmann JM
J Clin Pharmacol; 1996 Oct; 36(10):874-83. PubMed ID: 8930773
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
Brennan BJ; Xu ZX; Grippo JF
Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
